Abstract: A method for providing progestogen only contraception.

Abstract: A method for providing progestogen only contraception.

Abstract: A method for providing progestogen only contraception.

Abstract: Based on specific experimental studies the invention relates to an optimized levonorgestrel-only-composition for improved continuous oral contraception with consequences for suitable pharmaceutical preparations for the same purpose and with defined levonorgestrel content. The invention relates to a pharmaceutical composition for oral contraception for a woman of fertile age consisting of 60 to 100 ?g of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients. Furthermore, the invention relates to a pharmaceutical preparation for oral contraception consisting of a number of separately packed and individually removable daily dosage units intended for consecutive daily oral administration, each dosage unit consisting of 60 to 100 ?g of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients. Additionally, the invention relates to a dosage regimen, i.e.

Abstract: The use of melatonin for the production of peroral pulsatile forms of medications assures the safeguard of an effective level of the medical substance of melatonin in the blood, and which realize a relatively short invasion phase with a controlled delivery in comparison to conventional forms of medication containing melatonin, and which simultaneously exclude the known side effects. A control of the delivery of the melatonin is effected which is associated with the precise adaptation to the illness episodes or the pain attacks of certain illnesses, which can be treated prophylactically and therapeutically with the active agent melatonin.

Abstract: This invention relates to a compound preparation for contraception and hormone replacement that consists of three steps totalling 28 daily doses. The pharmaceutical is characterized in thatstep 1 consists of 3 or 4 daily doses, each containing a preparation in which the active ingredient is at least one biogenous estrogen component,step 2 consists of 20 to 22 daily doses, each containing a preparation in which the active ingredients are at least one biogenous estrogen and one gestagen component from the group of C.sub.21 -gestagens including progesterone, as well as dienogest, desogestrel, 3-keto desogestrel, gestodene, levonorgestrel, norgestimate, norethisterone, norethisterone acetate and dydrogesterone, andstep 3 consists of 3 or 4 daily doses, each containing a preparation in which the active ingredient is at least one biogenous estrogen component.

Abstract: A composition and methods useful for making such compositions and for using such compositions to destroy hydrogen peroxide in a liquid aqueous medium, such as that used to disinfect contact lenses, are disclosed. The composition comprises a coated core containing at least one hydrogen peroxide destroying component effective when released into a liquid aqueous medium to destroy or cause the destruction of hydrogen peroxide present in the liquid aqueous medium, and a barrier coating acting to substantially prevent the release of the hydrogen peroxide destroying component for a period of time after the composition is initially contacted with a hydrogen peroxide-containing liquid aqueous medium. The barrier coating is substantially water soluble, preferably includes polyvinylpyrrolidone and is applied as a substantially dry, solid material.

Abstract: A process of coating a particulate medicinal agent; comprising the application to said medicinal agent of a liquid composition containing a water-insoluble film-forming agent, a lipophilic solvent, a hydrophilic solvent and water, said liquid composition comprising an emulsion with at least two phases, wherein the liquid components of the liquid composition are removed after application of said liquid composition to said particulate medicinal agent.

Abstract: What are disclosed are methods for making a suspension suitable for use as a coating agent for medicaments by suspending a powder of certain vinyl copolymers in an aqueous solution or suspension of a plasticizer therefor, methods for converting such a suspension of copolymer in plasticizer into a film-forming solution or other extensively homogeneous phase, such suspensions and the film-forming conversion products thereof, and methods for coating medicaments with such suspensions and film-forming conversion products.